Tumor Marker Diagnostic Technologies: Assessment of Current and Emerging Technologies, And Their Potential Market Applications

NEW YORK, Aug. 18, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Tumor Marker Diagnostic Technologies: Assessment of Current and Emerging Technologies, And Their Potential Market Applications

http://www.reportlinker.com/p0591353/Tumor-Marker-Diagnostic-Technologies-Assessment-of-Current-and-Emerging-Technologies-And-Their-Potential-Market-Applications.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic

This 110-page report provides:

  • Assessments and potential applications of monoclonal antibodies, immunoassays, DNA probes, biochips/microarrays, chromosome analysis, IT, flow cytometry and biosensors or tumor marker diagnostic testing.
  • Review of competing/complementing technologies, such as CT, MRI, NMR, PET and photonics spectroscopy.

Contains 110 pages

Table of Contents

Current and Emerging Technologies

1. Monoclonal and Polyclonal Antibodies

2. Immunoassays

a. Technological Principle

b. Radioimmunoassay (RIA)

c. Enzyme Immunoassays (EIA)

Overview

ELISA

Immunofiltration

ParticleMembrane Capture Immunoassay

Enzyme Amplification

d. Fluorescent Immunoassays

e. Luminescence

Chemiluminescence

Bioluminescence

3. Molecular Diagnostics

a. Technology Overview

b. Amplification Methods

PCR

DAPPCR

ImmunoPCR

QCPCR

CAR

DNA

HPA

LCR

NASBA

QBR

SDA

3 SR, and others

4. Chromosome Analysis

a. Chronic Myelogenous Leukemia (CML)

b. Acute Myeloid Leukemia (AML)

c. Acute Lymphoblastic Leukemia (ALL)

d. Malignant Lymphomas

Lymphoid Malignancies

e. Chronic Lymphocytic Leukemia (CLL)

f. Solid Cancers

g. Chromosomal Translocation and Oncogenes

5. Artificial Intelligence

6. Flow Cytometry

7. TwoDimensional Gel Eletrophoresis (2DGE)

8. Biosensors

E. Competing/Complementing Technologies

1. CT

2. MRI

3. NMR

4. PET

5.Photonics Spectroscopy

To order this report:

In Vitro Diagnostic Industry: Tumor Marker Diagnostic Technologies: Assessment of Current and Emerging Technologies, And Their Potential Market Applications

In Vitro Diagnostic Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg

Reportlinker

Email: [email protected]

US: (805)652-2626

Intl: +1 805-652-2626

SOURCE Reportlinker

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.